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oseltamivir carboxylate, a neuraminidase inhibitor, using their deuterated analogs as internal
standards (ISs). The method involved solid phase extraction of the analytes and ISs from 200 mL
human plasma with no reconstitution and drying steps. The chromatographic separation was
achieved on a Symmetry C18 (100 mm 4.6 mm, 5 mm) column using 10 mM ammonium formate
and acetonitrile (30:70, v/v) as the mobile phase in a run time of 2.0 min. Quantitation of analytes
and ISs were done by multiple reaction monitoring on a triple quadrupole mass spectrometer in the
positive ionization mode. The linearity of the method was established in the concentration range of
0.5–200 ng/mL and 2.0–800 ng/mL for oseltamivir and oseltamivir carboxylate respectively. The
mean extraction recovery for oseltamivir (94.4%) and oseltamivir carboxylate (92.7%) from spiked
plasma samples was consistent and reproducible. The application of this method was demonstratedrsity. Production and hosting by Elsevier B.V. All rights reserved.
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Oseltamivir (OST) is a potent neuraminidase inhibitor that is
effective against both inﬂuenza A and inﬂuenza B. It selec-
tively inhibits the neuraminidase enzymes that are essential for
the release of progeny inﬂuenza viruses from host cells, and
thus prevents infection of new host cells and viral spread
throughout the respiratory tract [1,2]. OST (as oseltamivir
phosphate, Tamiﬂus) is an ethyl ester prodrug which is
readily absorbed from the gastrointestinal tract with an
absolute bioavailability of 75–80%. It is rapidly hydrolyzed
in vivo by hepatic carboxyesterases to its active metabolite
oseltamivir carboxylate (OSTC) [3]. Following oral adminis-
tration of OST in healthy volunteers, oseltamivir carboxylate
is detectable in plasma in about 30 min, while the maximum
plasma levels (Cmax) are attained within 5 h [4]. OST is
eliminated primarily by renal excretion of the active metabolite
(63% as OSTC and 3% of 100 mg dose as unchanged drug).
OSTC is only about 43% protein bound and has a relatively long
elimination half-life of 6–10 h. Further, variations in OST
pharmacokinetic parameters in patients with mild to moderate
hepatic or renal impairment are not clinically signiﬁcant [5,6].
Several assays have been reported for the determination of
oseltamivir and/or its active metabolite oseltamivir carbox-
ylate in different biological matrices such as rat plasma [7–10],
mouse plasma [9], rat urine [9], rat cerebrospinal ﬂuid [10], rat
brain [10], rat dried blood spot (DBS) [11], human DBS [11],
human saliva [12], human urine [9,10,12,13], human blood [13],
human tissue [13], human serum [14] and human plasma
[9,10,12,15–18]. Although there are many reports dealing with
simultaneous estimation of OST and OSTC in biological
samples [8–12,16,18], relatively few methods have been used
for bioequivalence/pharmacokinetic study in patients [18] or
healthy volunteers [4,5,14]. Moreover, there are no reports
on such studies done with Indian subjects. Schentag and
co-workers [4] have studied pharmacokinetics of OST and
OSTC in healthy Japanese and Caucasian subjects with 75 and
150 mg OST doses. The study showed similar pharmacoki-
netics in both type of subjects. In another report, the
pharmacokinetics and tolerability of oral OST was investi-
gated in healthy and elderly subjects [5]. Bahrami et al. [14]
have determined OSTC in human serum by HPLC–UV and
applied the method for a cross-over bioequivalence study of
two OST preparations in 24 healthy volunteers. Kanneti et al.
[16] proposed a highly rapid method for determination of OST
and OSTC in spiked human plasma; however, the pharmaco-
kinetic data were not presented. Very recently, Kromdijk et al.
[18] described a method for determination of OST and OSTC
in human ﬂuoride EDTA plasma by LC–ESI–MS/MS with a
sensitivity of 3.0 and 10 ng/mL respectively employing 50 mL
plasma samples. The method was used to determine both the
analytes in speciﬁc patient populations to evaluate current
dosing regimen. A comparative assessment of different meth-
ods developed for OST and/or OSTC in rat and human
plasma is presented in Table 1.Development of reliable, rugged and sensitive methods for
the simultaneous determination of OST and OSTC is essential
as the ex vivo stability of OST is a major concern due to
its rapid conversion to OSTC by plasma esterase enzymes,
which can lead to pharmacokinetic variations [18]. Further,
to establish suitable dosing regimens it is indispensable to
consider different populations for pharmacokinetic/bioequi-
valence applications. Thus, in the present work a highly
sensitive and selective LC–MS/MS method has been devel-
oped for measuring plasma concentration of OST and OSTC.
The method offers reduced overall analysis time (extraction
and chromatography) with minimum matrix interference and
requires low amounts of toxic organic solvents for sample
analysis. The wide linear dynamic concentration range ensures
estimation of the analytes with desired accuracy and precision
in human volunteers for a bioequivalence study. Further, the
assay reproducibility is successfully demonstrated by reanaly-
sis of 151 subject samples.2. Experimental
2.1. Chemicals and materials
Reference standards of OST (purity, 99.9%), OSTC (purity,
99.3%), oseltamivir-d5 (IS-1, purity, 100%) and oseltamivir
carboxylate-C13-d3 (IS-2, purity, 98.0%) were procured from
Hetero Drugs Limited (Hyderabad, India), Neucon Pharma
Pvt. Ltd. (Goa, India), Vivan Life Sciences Pvt. Ltd. (Mum-
bai, India) and Clearsynth Labs Pvt. Ltd. (Mumbai, India)
respectively. HPLC grade methanol, acetonitrile, ammonium
formate and formic acid were obtained from Merck Specialties
Pvt. Ltd. (Mumbai, India). Dichlorvos was obtained from
Sigma Aldrich Chemicals Pvt. Ltd. (Bangalore, India). Orochem
DVB-LP (30 mg, 1 cc) cartridges were obtained from Orochem
Technologies Inc. (Illinois, USA). Water used in the entire
analysis was prepared using Milli-Q water puriﬁcation system
from Millipore (Bangalore, India). Blank human plasma was
obtained from Supratech Micropath (Ahmedabad, India) and
was stored at 20 1C until use.
2.2. Liquid chromatography and mass spectrometric
conditions
A Shimadzu LC-VP HPLC system (Kyoto, Japan) was used
for chromatographic separation of OST, OSTC, IS-1 and IS-2
on a Symmetry C18 (100 mm 4.6 mm, 5 mm) analytical
column, maintained at 40 1C in the column oven. For isocratic
elution, the mobile phase consisting of 10 mM ammonium
formate and acetonitrile (30:70, v/v) was delivered at a ﬂow-
rate of 1.0 mL/min. The total eluate from the column was split
in 70:30 (v/v) ratio; ﬂow directed to the electrospray interface
was equivalent to 300 mL/min. The autosampler temperature
was maintained at 5 1C and the average pressure of the system
was 1500 psi. A triple quadrupole mass spectrometer, MDS
Table 1 Comparison of salient features of the present method with reported procedures for OST and OSTC in rat and human plasma.
Sr.
no.
Technique; LLOQ
(OST/OSTC)
Extraction method; sample
volume for processing; internal
standard; mean recovery
(OST/OSTC)
Retention time (OST/OSTC); run time; injection
volume; maximum on-column loading at ULOQ per
injection volume (OST/OSTC)
Organic solvent
consumption
(extraction and
chromatography)
per sample analysis
Post-column infusion study;
matrix factor (OST/OSTC);
application; incurred sample
reanalysis
Ref.
1 LC–MS/MS; 1.0/10.0 ng/
mL in human plasma
–; –; d3-Ro 640796 and d3-Ro
640802; –/–
– – –; –; pharmacokinetic study in 14
Japanese and 14 Caucasian
healthy subjects; –
[4]
2a HPLC–Fluorescence; –/
25 ng/mL in rat plasma
SPE followed by derivatization;
100 mL rat plasma; GS 4057; –/
4 68%
–/5.2 min; 10.0 min; 40 mL;–/64 ng App. 6.0 mL – [7]
3 LC-MS/MS; 1.0/10 ng/mL
in rat plasma
SPE; 50 mL rat plasma;
cephalexin; 94.7 to 103.8% for
both the analytes
1.38/1.16 min; 5.0 min; 100 mL; 33.3/333.3 ng App. 3.5 mL –; –; pharmacokinetic study in 5
male Sprague-Dawley rats; –
[8]
4 LC–MS/MS; 1.0/10 ng/mL
in rat/human plasma
SPE; 100 mL rat/human plasma;
GS 4723 and GS 5209; 84.8/
95.4%
5.0/3.5 min; 7.0 min; 100 mL; 16/666 ng App. 6.5 mL –; –; clinical and pre-clinical
pharmacokinetic study; –
[9]
5 LC–MS/MS; 0.1/0.1 ng/mL
in rat plasma and 1.0/
1.0 ng/mL in human plasma
PP followed by on-line SPE;
50 mL rat/human plasma; OST-
d3, OSTC-d3; 97.1/96.7%
2.65/2.24 min; 3.6 min; 5 mL for human plasma and
50 mL for rat plasma; 100 ng in rat plasma and 1250 ng
in human plasma for OST & OSTC respectively
App. 4.0 mL Yes; 0.99–1.14 for both the
analytes; pharmacokinetic study
in rats; –
[10]
6 LC–MS/MS; 1.0/10 ng/mL
in human plasma
SPE 96-well plate; 50 mL human
plasma; OST-d3, OSTC-
d3;490% for both
1.66/ 0.77 min; 4.0 min; 2.5 mL; 93 pg/1.3 ng App. 5.0 mL Yes; 0.98–1.13 for both the
analytes; –; –
[12]
7b HPLC–Fluorescence;
50 ng/mL/– in human
plasma
LLE followed by derivatization;
1000 mL human plasma;
mexiletine hydrochloride;
100.2%/–
9.72 min/–; 20.0 min; 20 mL; 15 ng/– App. 17.0 mL –; application in spiked plasma
samples; –
[15]
8 LC–MS/MS; 0.92/5.22 ng/
mL in human plasma
SPE; 500 mL human plasma;
acyclovir; 68.7/70.7%
0.39/0.38 min; 1.0 min; 5 mL; 9.3/6.2 ng App. 2.0 mL – [16]
9b Spectroﬂuorimetry; 16 ng/
mL/– in human plasma
LLE followed by derivatization;
1000 mL human plasma; –;
98.7%
– – –; –; preliminary in vitro study in
spiked plasma samples; –
[17]
10 LC–MS/MS; 3.0/10 ng/mL
in human plasma
PP; 50 mL human plasma; OST-
d5 and OSTC-C13-d3; 97.4/
104.3%
5.0/4.7 min; 9.0 min;10 mL; 1.5/50 ng App. 2.0 mL –;app. 0.94/1.03; pharmacokinetic
study in one patient; –
[18]
11 LC–MS/MS; 0.5/2.0 ng/mL
in human plasma
SPE; 200 mL human plasma;
OST-d5 and OSTC-C13-d3;
94.4/92.7%
1.56/1.11 min; 2.0 min; 10 mL; 5/20 pg App. 2.0 mL Yes; app. 0.99/0.98;
bioequivalence study in 42
healthy volunteers; % change
within718.0
PW
aOnly oseltamivir carboxylate.
bOnly oseltamivir; OST: oseltamivir; OSTC: oseltamivir carboxylate; LLOQ: lower limit of quantitation; ULOQ: upper limit of quantitation; SPE: solid phase extraction; PP: protein
precipitation; LLE: liquid-liquid extraction; PW: present work, App.: approximately.
D
eterm
in
a
tio
n
o
f
o
selta
m
iv
ir
a
n
d
o
selta
m
iv
ir
ca
rb
o
x
y
la
te
in
p
la
sm
a
b
y
L
C
–
M
S
/M
S
1
5
1
A. Gupta et al.152SCIEX API-4000 (Toronto, Canada), equipped with electro
spray ionization and operating in positive ionization mode
was used for detection of analytes and ISs. For quantitation,
multiple reaction monitoring (MRM) was used to monitor
precursor-product ion transitions at m/z 313.1-166.2,
285.1-138.1, 318.1-171.2 and 289.2-138.3 for OST,
OSTC, IS-1 and IS-2 respectively. The source dependent
parameters set, nitrogen (purity, 99.95%) as Gas 1 (nebulizer
gas) and Gas 2 (heater gas), ion spray voltage, heater
temperature, curtain gas nitrogen and collisional activation
dissociation were optimized at 40 psig and 60 psig, 4000 V,
400 1C, 10 psig and 3 psig respectively. Other compound
dependent parameters like declustering potential, entrance
potential, collision energy and exit cell potential were main-
tained at 15.0, 10.0, 25.0 and 10.0 V respectively for both the
analytes and ISs, while the dwell time was set at 200 ms. Data
collection, peak integration, and calculations were performed
using the Analyst software version 1.4.2.
2.3. Calibration standards and quality control samples
Stock solutions of OST (1000 mg/mL) and OSTC (1000 mg/
mL) were prepared by dissolving accurately weighed reference
standards in water. Mixed stock solution of OST (100 mg/mL)
and OSTC (400 mg/mL) was prepared by taking 200 mL of
OST and 800 mL of OSTC stock solution and made up to
2.0 mL with dichlorvos solution (4 mg/mL in acetonitrile ).
Working solutions of the analytes were prepared by serial
dilution of mixed stock solution in dichlorvos solution.
Calibration standards (CSs) and quality control (QC) samples
were prepared by spiking blank plasma (2% of total volume of
blank plasma) with mixed stock solutions. CSs were made at
0.5, 1.0, 4.0, 10.0, 20.0, 40.0, 100 and 200 ng/mL concentra-
tions for OST and 2.0, 4.0, 16.0, 40.0, 80.0, 160, 400 and
800 ng/mL concentrations for OSTC. QC samples were pre-
pared at four concentration levels, 160/640 ng/mL (HQC, high
quality control), 80.0/320 ng/mL (MQC, medium quality
control), 1.5/6.0 ng/mL (LQC, low quality control) and
0.5/2.0 ng/mL (LLOQ QC, lower limit of quantiﬁcation
quality control) for OST/OSTC respectively. Stock solutions
of IS-1 and IS-2 (200 mg/mL each) were prepared by dissol-
ving requisite amount in water. An aliquot of 25 mL of IS-1
(200 mg/mL) and 500 mL of IS-2 (200 mg/mL) was further
diluted to 100 mL with dichlorvos solution to obtain a
solution of 50 ng/mL for IS-1 and 1000 ng/mL for IS-2. All
the solutions (standard stock, CSs and QC samples) were
stored at 5 1C until use.
2.4. Sample extraction procedure
Prior to analysis, all frozen subject samples, CSs and QC
samples were thawed in ice bath maintained below 10 1C. To
an aliquot of 200 mL of spiked plasma sample, 50 mL of
mixed internal standard was added and vortexed for 15 s.
Further, 500 mL of 1.0% formic acid in water was added
and vortexed for another 15 s. Samples were then centri-
fuged at 3204 g for 2 min at 10 1C and loaded on Orochem
DVB-LP (1 cc, 30 mg) extraction cartridges which were
preconditioned with 1 mL of methanol followed by 1 mL of
water. The cartridges were washed twice with 1% formic
acid in water. The analytes and ISs were eluted with 0.2 mLof dichlorvos solution (0.1 mg/mL in acetonitrile): water
(70:30, v/v). Samples were transferred to pre-labeled auto-
sampler vial and 10 mL was used for injection in the
chromatographic system.2.5. Procedures for method validation
The method was validated as per the USFDA guidelines
[19,20]. System suitability experiment was performed by
injecting six consecutive injections using aqueous standard
mixture of OST (80 ng/mL), OSTC (320 ng/mL), IS-1 (500
ng/mL) and IS-2 (1000 ng/mL) at the start of each batch
during method validation. System performance was studied by
injecting one extracted LLOQ sample with IS and the auto-
sampler carryover of analytes was experimentally determined
by sequentially injecting extracted blank plasma-upper limit
of quantitation (ULOQ) sample-extracted blank plasma-
LLOQ sample-extracted blank plasma at the beginning of
each analytical batch.
The selectivity of the method was evaluated by analyzing
ten different batches of plasma, which included seven
K3EDTA and one each of lipidemic, haemolysed and hepar-
inised plasma. Interference of commonly used medications by
human volunteers was checked for acetaminophen, cetirizine,
domperidone, ranitidine, diclofenac, ibuprofen, nicotine and
caffeine in six different batches of plasma having K3EDTA as
an anticoagulant. Their stock solutions were prepared by
dissolving requisite amount in methanol and water (50:50,
v/v). Further, a mixed working solution of acetaminophen
(1000 mg/mL), cetirizine (20 mg/mL), domperidone (1 mg/
mL), ranitidine (27.5 mg/mL), diclofenac (100 mg/mL), ibu-
profen (2250 mg/mL), nicotine (5 mg/mL) and caffeine
(1000 mg/mL) was prepared in the same diluents, spiked in
plasma and analyzed under the same conditions at LQC and
HQC levels in six replicates. These sets were processed
along with freshly prepared CSs and qualifying QC samples
in duplicate.
The linearity of the method was ascertained by measuring
the peak area ratio response (analyte/IS) for ﬁve calibration
curves containing eight non-zero concentrations. Each cali-
bration curve was analyzed individually by using least square
weighted (1/x2) linear regression.
Intra-batch accuracy and precision (% CV) were deter-
mined in six replicates of QC samples along with CSs. The
inter-batch accuracy and precision were assessed by analyzing
ﬁve precision and accuracy batches on three consecutive days.
Reinjection reproducibility was also checked by re-injecting
one entire validation batch.
The extraction recovery for analytes and ISs was calculated
by comparing the mean area response of extracted samples
(spiked before extraction) with that of unextracted samples
(spiked after extraction) at HQC, MQC and LQC levels.
Matrix effect (expressed as internal standard normalized
matrix factor) was assessed by comparing the mean area
response of unextracted samples (spiked after extraction) with
mean area of neat standard solutions at three QC levels.
Qualitative illustration of matrix ion suppression/enhance-
ment was conducted by post column infusion of analytes
(MQC level) at 10 mL/min by a Harvard infusion pump
through a ‘T’ connector [21].
Determination of oseltamivir and oseltamivir carboxylate in plasma by LC–MS/MS 153Stability was examined by measuring the area ratio response
(analyte/IS) of stability samples against freshly prepared com-
parison standards at LQC and HQC levels. Stock and working
solutions of analytes and mixed ISs solutions were checked for
short term stability at room temperature and long term stability
at 5 1C. Autosampler stability (wet extract), bench top (at room
temperature) stability and freeze-thaw stability were determined
at LQC and HQC using six replicates at each level. Long term
stability of spiked plasma samples stored at 20 1C and 70 1C
was also studied at both these levels.
Method ruggedness was evaluated on two precision and
accuracy batches. The ﬁrst batch was analyzed by different
analysts while the second batch was studied on two different
equipments and columns of the same make. Dilution relia-
bility was determined by diluting the stock solution prepared
as spiked standard at 300 ng/mL for OST and 1200 ng/mL for
OSTC in the screened plasma. The precision and accuracy for
dilution integrity standards at 1/2 and 1/10th dilution were
determined by analyzing the samples against freshly prepared
CSs.
2.6. Application of the method in healthy subjects and incurred
sample reanalysis
The validated method was applied to quantify plasma OST
and OSTC concentration for a bioequivalence study in 42
healthy Indian subjects after oral administration of test (75 mg
capsules from an Indian Company) and a reference (TAMI-
FLUs, 75 mg oseltamivir phosphate capsules from Genentech
USA Inc., USA) formulation under fed conditions. Written
consent was taken from all the subjects after informing themFig. 1 Q3 mass spectra of (A) oseltamivir (OST, m/z 313.1-166.2,
m/z 285.1-138.1, scan range 50–360 amu) in the positive ionizationabout the objectives and possible risks involved in the study.
The study was conducted strictly in accordance with the
guidelines laid down by International Conference on Harmo-
nization and USFDA [22]. Blood samples were collected at 0.0
(pre-dose), 0.25, 0.50, 0.75, 1.00, 1.50, 2.00, 2.50, 3.00, 3.50,
4.00, 4.50, 5.00, 5.50, 6.00, 6.50, 7.0, 8.0, 9.0, 10.0, 12.0, 24.0,
36.0 and 48.0 h after oral administration of test and reference
formulation in labeled K3EDTA-vacutainers placed in an ice
bath maintained below 10 1C. Plasma was separated through
centrifugation and transferred to polypropylene tube contain-
ing 4 mg/mL of dichlorvos stock solution (plasma to dichlor-
vos stock solution ratio was 95:5, v/v). The samples were
kept frozen at 20 1C till the completion of both the periods
and then below 70 1C until analysis. The pharmacokinetic
parameters for OST and OSTC were estimated by non-
compartmental model using WinNonlin software version 5.3
(Pharsight Corporation, Sunnyvale, CA, USA). An incurred
sample re-analysis (ISR) was also conducted by selection of
151 subject samples near Cmax and in the elimination phase of
the pharmacokinetic proﬁles. As per the acceptance criterion
the percent change in the values should not be more than
720% [23].3. Results and discussion
3.1. Mass spectrometry
The present study was conducted using electrospray ionization
(ESI) in the positive mode as OST, OSTC, IS-1 and IS-2 have
primary and secondary amino groups. Initially, the precursorscan range 50–360 amu) and (B) oseltamivir carboxylate (OSTC,
mode.
A. Gupta et al.154and product ions were optimized by infusing 500 ng/mL solu-
tions in the mass spectrometer between m/z 50 and 360 range in
the positive as well as negative modes. However, it was difﬁcult
to get the deprotonated precursor ion for OST in the negative
mode and hence positive ionization mode was selected. Further,
the use of 0.1% formic acid in the mobile phase improved the
response of protonated precursor [MþH]þ ions at m/z 313.1,
285.1, 318.1 and 289.2 for OST, OSTC, IS-1 and IS-2 respec-
tively in the full scan mass spectra as observed previously [18].
Most intense and consistent product ions for OST, OSTC, IS-1
and IS-2 were found at m/z 166.2, 138.1, 171.2 and 138.4
respectively by applying 25 eV collision energy (Fig. 1). The ions
at m/z 166.2 and 138.1 for OST and OSTC respectively can be
attributed to the loss of formamide and pentyloxy groups from
the precursor ions. The MRM parameters like nebulizer gas,
heater gas ﬂow, ion spray voltage and source temperature were
suitably optimized to obtain a consistent and adequate response
for the analyte. A dwell time of 200 ms for OST, OSTC, IS-1
and IS-2 was adequate and no cross talk was observed between
their MRMs.
3.2. Optimization of extraction procedure
Due to rapid hydrolysis of OST into its active metabolite OSTC
it is essential to use an esterase enzyme inhibitor for their
simultaneous determination, especially during a clinical study
[24]. Wiltshire et al. [9] carried out extensive stability study for
OST in dichlorvos (an esterase inhibitor) treated plasma samples
from humans, rat, mouse, marmoset, rabbit and ferret. Simi-
larly, Lindega˚rdh and co-workers [12] have successfully used
ﬂuoride/oxalate to stabilize OST in human plasma, urine and
saliva. Furthermore, Chang et al. [8] have shown that hydrolysis
can also be controlled by keeping the samples on ice and that
there is no change in OST concentration up to 1 h. Based on
these observations, the working solutions of OST and OSTC
used for spiking blank plasma were prepared in dichlorvos
solution (4 mg/mL in acetonitrile), while plasma obtained from
subject samples was directly collected in tubes containing
dichlorvos solution to ensure sample integrity. Further, the
entire extraction process was carried out in ice bath maintained
below 10 1C. Reported procedures have employed protein
precipitation (PP) [18], liquid–liquid extraction (LLE) [15,17],
solid phase extraction (SPE) [7–9,12–14,16] or a combination of
PP and on-line SPE [10] for sample preparation of OST and/or
OSTC from different biological samples. Thus, PP was tried
with trichloroacetic acid in water (5–10%) as reported earlier
[18]. Although the extracts obtained were clear with adequate
response for both the analytes, the recovery was inconsistent for
OST at CS-1 (0.5 ng/mL) and CS-2 (1.0 ng/mL) levels. Thus,
SPE was initiated on Orochem DVB-LP extraction cartridges
under acidic conditions to remove plasma proteins and other
interfering substances to obtain clean extracts for
LC–MS/MS analysis. Use of 0.2 mL of dichlorvos solution
(0.1 mg/mL in acetonitrile): water (70:30, v/v) as the eluting
solvent helped in reproducible and quantitative recovery for
both the analytes without drying and reconstitution steps.
3.3. Chromatography
Earlier methods have used different columns such as Nova-
Pak CN HP [8], ZIC-HILIC [12], Chromatopack C18 andSynergi Hydro C18 with varying dimensions and particle size
for separation of OST and OSTC from different matrices.
Thus, analytical potential of four columns namely Symmetry
C18 (100 mm 4.6 mm, 5 mm), ACE CN (100 mm 4.6 mm,
5 mm), Cosmosil C18 (100 mm 4.6 mm, 5 mm) and Alltima
C18 (150 mm 4.6 mm, 5 mm) were tested to achieve adequate
retention and separation, short run time, symmetric peak
shape and sufﬁcient response for the analytes. Separation
was tried using various combinations of acetonitrile/methanol
and additives like formic acid (0.1%) and ammonium formate
(5–10 mM). ACE CN column gave poor response and peak
shapes, while Cosmosil C18 afforded adequate retention
but the response was inadequate for both the analytes. The
response obtained on Alltima C18 was satisfactory; however,
the peak shape was unacceptable. Nevertheless, the best
chromatographic conditions as a function of analyte peak
intensity, peak shape, adequate retention and analysis run
time were achieved on Symmetry C18 (100 mm 4.6 mm,
5 mm) using 10 mM ammonium formate and acetonitrile
(30:70, v/v) as the mobile phase under isocratic conditions
(Fig. 2). At the same time it afforded baseline separation
(resolution factor Rs, 1.1) of the analytes within 2.0 min, with
a retention time of 1.56 and 1.11 min for OST and OSTC
respectively. The chromatographic run time achieved in the
present work was the shortest compared to all previous assays
except one report [16], which had a run time of 1.0 min.
Further, the reproducibility in the measurement of retention
time for both the analytes, expressed as % CV wasr0.7% for
more than 100 injections on the same column. The on-column
loading of analytes for an injection volume of 10 mL at ULOQ
was much less as compared to other methods (Table 1). The
deuterated internal standards used in the study helped in
overall assay performance and the accuracy of the data.
Moreover, deuterated internal standards had similar extrac-
tion recovery as the non-labeled analytes.
3.4. Validation results
3.4.1. Assay performance and carryover
The precision (% CV) for system suitability test was in the
range of 0.04–0.57% for the retention time and 0.81–1.98%
for the area response of both the analytes and ISs. The signal
to noise ratio for system performance was Z30 for both the
analytes and ISs. Autosampler carry-over evaluation was
performed to ensure that it does not affect the accuracy
and the precision of the proposed method. There was
negligible carryover (r 3.3% for OST andr4.5% for OSTC
of LLOQ area) observed in extracted blank plasma after
subsequent injection of highest CS at the retention time of the
analytes.
3.4.2. Method selectivity
Representative MRM chromatograms of extracted blank
human plasma (Fig. 2A and E), blank plasma spiked with
IS (Fig. 2B and F), OST and OSTC at LLOQ (Fig. 2C and G)
and a subject sample at Cmax after administration of 75 mg
dose of oseltamivir phosphate (Fig. 2D and H) demonstrate
the selectivity of the method. No endogenous compounds were
found to interference at the retention time of analytes and ISs.
Moreover, none of the medications commonly used by human
volunteers such as acetaminophene, cetirizine, domperidone,
Fig. 2 Representative chromatograms of (A–D) oseltamivir (m/z 313.1-166.2) and oseltamivir-d5 (IS-1, m/z 318.1-171.2) and (E–H)
oseltamivir carboxylate (m/z 285.1-138.1) and oseltamivir acid-C13-d3 (IS-2, m/z 289.2-138.3) in (A) & (E) double blank plasma,
(B) & (F) blank plasma spiked with IS, (C) & (G) analytes at LLOQ and IS, (D) & (H) real subject sample at Cmax after administration of
75 mg dose of oseltamivir phosphate.
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fered with the quantitation of analytes.3.4.3. Linearity, sensitivity, accuracy and precision
Both the analytes showed good linearities (r2Z0.9976) through
the studied concentration range of 0.5–200 ng/mL for OST and
2.0–800 ng/mL for OSTC. The mean linear equations for
calibration curve concentrations were y¼(0.376170.0429)xþ
(0.003970.0060) for OST and y¼(0.054970.0135)xþ(0.02717
0.0095) for OSTC. The lowest concentration (LLOQ, 0.5 ng/mL
and 2.0 ng/mL) in the standard curve was measured at a signal-
to-noise ratio (S/N)Z30. Based on the high S/N values it was
possible lower the quantitation limit by 3 folds; however, it not
required based on subject sample results. The sensitivity
achieved for OST and OSTC in the present work was higher
compared to all other methods developed in human plasma[9,10,12,15–18]. The LOD values found at S/NZ10 (% CV less
than 15) were 0.15 and 0.62 ng/mL for OST and OSTC
respectively. The intra-batch and inter-batch precision and accu-
racy results at four QC levels are presented in Table 2. The preci-
sion (% CV) and accuracy values for intra- and inter-batch ranged
from 2.42% to 5.17% and 100.2% to 103.8% for OST, and
1.87% to 4.57% and 94.5% to 102.5% for OSTC respectively.3.4.4. Recovery and ion suppression
The extraction recovery at three QC levels is shown in Table 3.
The mean extraction recovery for OST, OSTC, IS-1 and IS-2
was 94.4%, 92.4%, 93.1% and 91.9% respectively. Post
column infusion chromatograms in Fig. 3A–D do not show
any ion suppression or enhancement at the retention time of
analytes and ISs. Moreover, the internal standard normalized
matrix factors varied from 0.99 to 1.02 for OST and 0.98 to
Table 2 Intra-batch and inter-batch precision and accuracy for oseltamivir and oseltamivir carboxylate.
Analyte Nominal
concentration
(ng/mL)
Intra-batch (n¼6; single batch) Inter-batch (n¼30; 6 from each batch)
Mean concentration
found (ng/mL)
Precision
(%)
Accuracy
(%)
Mean concentration
found (ng/mL)
Precision
(%)
Accuracy
(%)
Oseltamivir 0.500 0.501 2.42 100.2 0.507 4.54 101.4
1.50 1.51 5.17 100.7 1.54 4.60 102.7
80.0 80.7 3.57 100.9 82.8 3.30 103.5
160.0 166.0 3.88 103.8 165.1 3.19 103.1
Oseltamivir
carboxylate
2.0 2.02 4.57 101.0 1.89 3.09 94.5
6.0 5.96 2.21 99.3 5.87 4.16 97.8
320.0 321.0 2.60 100.3 328.0 4.33 102.5
640.0 632.0 1.87 98.7 638.0 2.81 99.7
Table 3 Extraction recovery for oseltamivir and oseltamivir carboxylate from human plasma (n¼6).
Parameter Oseltamivir Oseltamivir
carboxylate
Oseltamivir-
d5
Oseltamivir-
C13-d3
LQC MQC HQC LQC MQC HQC MQC MQC
Mean area response of samples prepared by spiking in
extracted blank plasma
11673 599841 1224582 8023 417103 863796 632317 40389
Mean area response of samples prepared by spiking
before extraction
11011 561212 1167134 7480 386995 796326 588542 37136
Recovery (%) 94.3 93.6 95.3 93.2 92.7 92.2 93.1 91.9
Mean recovery (%) 94.4 92.7
Precision (%) 3.99 3.71 2.77 3.59
Fig. 3 MRM LC–MS/MS chromatograms of blank plasma extract with post column infusion of (A) oseltamivir, (B) oseltamivir
carboxylate, (C) oseltamivir-d5 and (D) oseltamivir acid-C13-d3.
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Table 4 Matrix factor (internal standard normalized) for oseltamivir and oseltamivir carboxylate.
Plasma lot Oseltamivir Oseltamivir carboxylate
HQC MQC LQC HQC MQC LQC
Lot 1 0.99 1.00 1.03 1.00 0.98 0.97
Lot 2 0.98 0.99 1.01 1.01 1.00 0.97
Lot 3 0.98 0.98 0.98 1.00 0.98 0.96
Lot 4 1.00 0.99 1.06 0.99 0.99 0.97
Lot 5 (haemolysed) 0.99 1.00 1.01 0.99 0.98 1.02
Lot 6 (lipemic) 1.01 0.99 1.02 1.00 0.99 0.98
Mean matrix factor 0.99 0.99 1.02 0.99 0.99 0.98
Precision (%) 1.36 0.79 2.61 0.90 0.89 2.60
Table 5 Stability of oseltamivir and oseltamivir carboxylate under various conditions (n¼6).
Storage conditions Oseltamivir Oseltamivir carboxylate
Mean stability sample
(ng/mL)7SD
Change (%) Mean stability sample
(ng/mL)7SD
Change (%)
Bench top stability (ambient temperature); 12 h
HQC 167.079.5 0.60 653.1723.7 1.40
LQC 1.43070.043 2.14 5.84170.495 1.40
Wet extract stability(5 1C); 25 h
HQC 169.277.4 1.81 647.2718.2 0.47
LQC 1.48170.086 5.71 5.98370.556 4.55
Wet extract stability(25 1C); 10 h
HQC 172.1710.4 3.61 642.4713.4 0.31
LQC 1.46070.077 4.29 6.05070.393 5.77
Freeze & thaw stability in plasma; 5 cycles, 20 1C
HQC 159.379.1 3.05 626.2722.7 1.57
LQC 1.36470.075 4.23 5.58370.553 2.79
Freeze & thaw stability in plasma; 5 cycles, 70 1C
HQC 160.275.4 2.44 626.0725.6 1.57
LQC 1.44270.070 1.41 5.76270.394 0.35
Long term stability in plasma: 61 days, 20 1C
HQC 172.373.9 1.18 698.4716.6 0.85
LQC 1.63570.096 3.61 6.79170.273 2.72
Long term stability in plasma: 61 days, 70 1C
HQC 171.173.7 0.59 707.4719.0 0.43
LQC 1.63270.035 1.81 6.49270.328 1.82
Change%¼ Mean stability samples2Mean comparison samples
Mean comparison samples
 100
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which indicates minimum matrix interference and that the ISs
efﬁciently compensated for any possible ion suppression or
enhancement.
3.4.5. Stability results
Stability study for OST has been extensively discussed in
previous reports [8,9,23]. In the present method dichlorvos
was used as an esterase inhibitor to inhibit the metabolism of
OST in human plasma. Samples for short-term stability
remained stable up to 29 h at 25 1C, while the stock solutions
and working solution for long term stability were stable for
a minimum of 60 days at refrigerated temperature of 5 1C. Thedetailed results for different stability experiments in plasma
are shown in Table 5.3.4.6. Dilution reliability and method ruggedness
The precision (% CV) for dilution reliability of 1/2 and 1/10th
dilution was within 1.8% to 3.5%, while the accuracy results
were between 98.0% and 105.0% for both the analytes. For
method ruggedness the precision (% CV) and accuracy values
for two different equipments and with different analysts
ranged from 0.91% to 5.35% and 95.3% to 104.8% respec-
tively for both the analytes at three QC levels.
Fig. 4 Mean plasma concentration-time proﬁle of (A) oseltamivir and (B) oseltamivir carboxylate after oral administration of test
(75 mg oseltamivir phosphate capsule of an Indian Company) and a reference (TAMIFLUs, 75 mg oseltamivir phosphate capsule from
Genentech USA Inc., USA) formulation to 42 healthy Indian subjects under fed conditions.
Table 6 Mean pharmacokinetic parameters of oseltamivir and oseltamivir carboxylate (Mean 7SD).
Parameter Oseltamivir Oseltamivir carboxylate
Test Reference Test Reference
Cmax (ng/mL) 3279 36710 241764 249763
Tmax (h) 2.6970.96 2.6571.34 6.1571.15 6.2271.31
t1/2 (h) 4.8272.19 4.9773.27 7.6271.07 7.5070.96
Kel (1/h) 0.17670.078 0.19670.102 0.09370.013 0.09470.012
AUC 0–48 (h ng/mL) 145732 153735 37677656 39017721
AUC 0–inf (h ng/mL) 155732 163737 38637673 39937729
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The validated method was successfully used to quantify OST
and OSTC plasma concentration after administration of a
single 75 mg oral dose of oseltamivir phosphate. Fig. 4 shows
the plasma concentration vs. time proﬁle of OST and OSTC in
healthy Indian subjects under fed condition. Approximately
4200 samples including the calibration, QC and subject
samples were run and analyzed during a period of 12 days
and the precision and accuracy were well within the acceptablelimits. Table 6 summarizes the mean pharmacokinetic para-
meters obtained for OST and OSTC after oral administration
of test and reference formulation. The mean Cmax values
obtained for OST in the present work were comparable with a
similar study involving Japanese and Caucasian healthy
volunteers [4]. However, Cmax values for OSTC were signiﬁ-
cantly higher compared to Caucasian and to a lesser extent
with Japanese subjects for identical dose strength. Further,
Tmax, t1/2 and AUC values were all on the higher side in Indian
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due to several factors including race of subjects, gender, type
of food and others. However, the ratios of mean log-
transformed parameters and their 90% conﬁdence intervals
(90.07–96.74%) were within the acceptance range of 80–125%.
The precision (% CV) values for intra-subject variation ranged
from 6.43% to 6.55% for Cmax, AUC0t and AUC0–inf for
both the analytes. The assay reproducibility was established by
reanalysis of 151 incurred samples. Out of these, 114 samples
showed % change of 710%, while the remaining 37 samples
were within718.0% of the initial results for both the analytes.
This authenticates the reproducibility of the validated assay.4. Conclusion
A sensitive, selective and rapid method for the simultaneous
determination of OST and OSTC in human plasma has been
developed and fully validated as per USFDA guidelines. The
efﬁciency of SPE and a chromatographic run time of 2.0 min
per sample make it highly useful for high-throughput bioana-
lysis of OST and OSTC. Moreover, the present method does
not involve drying and reconstitution steps during sample
processing compared to other SPE procedures [8,9,16] or a
derivatization step post extraction [7]. The proposed method is
more sensitive for both the analytes compared to all other
methods developed in human plasma. The chromatographic
run time is shorter compared to all other methods except one
report [16]. The linear dynamic range ensures application of
the method for even higher dose strength with acceptable
precision and accuracy. With dilution reliability up to 2-folds,
it is possible to extend the upper limit of quantiﬁcation to 400
and 1600 ng/mL for OST and OSTC respectively. The vali-
dated method has shown acceptable precision and accuracy
for their simultaneous quantiﬁcation in human plasma in a
clinical study. Incurred sample reanalysis with 151 samples
demonstrates the reproducibility in the measurement of sub-
ject samples.
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